Renaissance Capital logo

NGSX News

ALERT: Top weekly perfomers: Rex Energy, NeurogesX, Babcock & Brown

The following companies were the top performing IPOs over the last five trading sessions:

...read more

Biotech NeurogesX prices below range

NeurogesX, which is developing pain management therapies based on known chemical entities, priced its 4 million shares at $11, 21% below the midpoint of the anticipated $13-$15 range, on Tuesday evening. Morgan Stanley was the lead manager on the deal. The stock...read more

Biopharmaceutical company NeurogesX announces terms

NeurogesX, a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced the terms of its IPO Tuesday. The company plans to offer 4 million shares at $13.00 to $15.00 per share. Morgan Stanley is the lead...read more

Biopharmaceutical company NeurogesX files for IPO

NeurogesX, a biopharmaceutical company focused on developing on commercializing novel pain management therapies, filed for an IPO on Wednesday. Morgan Stanley is the lead manager on the deal. Terms and timing are yet to be announced....read more

Archived Headlines